4 drug(s) with this reaction
5,080 total reports
Haemoglobin Decreased has been reported as an adverse reaction across 4 drug(s) manufactured by Abbvie Inc in the FDA Adverse Event Reporting System (FAERS) database. A combined total of 5,080 adverse event reports mention haemoglobin decreased in connection with Abbvie Inc products.
This page provides a breakdown of which Abbvie Inc drugs are most commonly associated with haemoglobin decreased, along with report counts and links to detailed safety analyses for each medication. Understanding which drugs from a single manufacturer share a common adverse reaction can help patients and healthcare providers identify potential class-wide safety patterns.
The following Abbvie Inc drugs have haemoglobin decreased listed in their FDA adverse event reports, sorted by report count:
In addition to haemoglobin decreased, the following adverse reactions have been reported across Abbvie Inc's drug portfolio:
4 drug(s) manufactured by Abbvie Inc have haemoglobin decreased listed in their FDA adverse event reports: LEVOTHYROXINE SODIUM, VENETOCLAX, FENOFIBRATE, PARICALCITOL.
There are a combined 5,080 reports of haemoglobin decreased across 4 Abbvie Inc drug(s) in the FDA adverse event database.